Mehmet Ali EKİCİ, Turgay BULUT, Bülent TUCER, Seyit Kaan BAŞARSLAN, Ali KURTSOY

Prognostic factors in patients with glioblastoma multiforme (clinical research)

To define the independent variables that affect the life spans of patients with glioblastoma multiforme (GBM). Materials and methods: This study was conducted in the neurosurgery clinic of Erciyes University's Faculty of Medicine, lasting from February 2000 to September 2006. A total of 98 patients were diagnosed with GBM after tumor resections. Patients' demographic, neurological, radiological, surgical, and clinical features and adjunct therapies were analyzed retrospectively. Results: Of the 98 patients, 36 (36.7%) were female and 62 (65.4%) were male. There were 15 patients (15.3%) still alive. The median survival time (MST) of the gross total resection and subtotal resection groups was 12 and 8 months, respectively. The group with postoperative Karnofsky performance scores (KPS) of =>70 included 56 patients; their survival rate was 19.6% and their MST was 14 months (confidence interval [CI] 95%, 10-18). The postoperative KPS of

Anahtar Kelimeler:

Key words: Glioblastoma multiforme, prognosis, postoperative tumor volume, Karnofsky performance score

Prognostic factors in patients with glioblastoma multiforme (clinical research)

Keywords:

Key words: Glioblastoma multiforme, prognosis, postoperative tumor volume, Karnofsky performance score,

PDF

___

Li SW, Qiu XG, Chen BS, Zhang W, Ren H, Wang ZC et al. Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J (Engl) 2009; 122: 1245–
Albert FK, Forsting M, Sartor K, Adams HP, Kunze S. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34: 45–1.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190–8.
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol 2004; 6: 227–35.
Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Rİnning P et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122: 159–
Burger PC, Green SB. Patient age, histological features, and length of survival in patients with glioblastoma multiforme. Cancer 1987; 59: 1617–25.
Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study. Cancer 1983; 52: 997–1007.
Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D et al. Brain Cancer Register of the Fondazione IRCCS (Istituto Ricovero e Cura a Carattere Scientifico) Istituto Neurologico Carlo Besta. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-Oncol 2008; 10: 79–87.
Stark AM, Stepper W, Mehdorn HM. Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC. Eur J Cancer Care (Engl) 2010; 19: 39–
Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC Press; 2000.
Sawaya R, Hammound M, Schoppa D, Hess KR, Wu SZ, Shi WM et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998; 42: 1044–56.
Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management adult malignant gliomas. Neurosurgery 1994; 35: 378–88.
Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U et al. Comparison of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67: 121–32.
Kelly PJ. Stereotactic biopsy and resection of thalamic astrocytomas. Neurosurgery 1989; 25: 185–95.
Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytoma in adults. J Neurosurg 1990; 73: 331–44.
Barker CA, Chang M, Chou JF, Zhang Z, Beal K, Gutin PH et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 2013; 113: 397–401.
Uzuka T, Aoki H, Natsumeda M, Takahashi H, Fujii Y. Effectiveness of maximal safe resection for glioblastoma including elderly and low Karnofsky performance status patients: retrospective review at a single institute. Neurol Med Chir (Tokyo) 2012; 52: 570–76.
Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality life in patients with supratentorial glioblastoma and anaplastic astrocytomas. Neurosurgery 1987; 21: 201–6.
Karnofsky DA, Burcheral JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of Chemotherapy Agents. New York: Colombia University Press; 1949. p.191–205.
Barker FG 2nd, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997; 79: 115–
Wang Y, Li S, Zhang Z, Chen X, You G, Yang P et al. Surgical extent impacts the value of the established prognosticators in glioblastoma patients: a prospective translational study in Asia. Head Neck Oncol 2012; 4: 80.
Bentzen SM, Thames HD. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncal Bio Phys 1996; 36: 247–51.
Yount GL, Haas-Kogan DA, Vidair CA, Haas M, Dewey WC, Israel MA. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res 1996; 56: 500–6.
Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L et al. p53-dependent G1 arrest and p53-independent apoptosis influence radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 1996; 36: 95–103.
Louis DN. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 1994; 53: 11–21.
Leenstra S, Bijlsma EK, Troost D, Oosting J, Westerveld A, Bosch DA et al. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 1994; 70: 684–9.
Tanaka S, Meyer FB, Buckner JC, Uhm JH, Yan ES, Parney IF. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg 2013; 118: 786–
Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK et al. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg 2011; 115: 754–59.
Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M et al. Associations of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 1996; 69: 236–40.
SongTao Q, Lei Y, Si G, YanQing D, HuiXia H, XueLin Z et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012; 103: 269–73.